Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response

Guanxi Qiao, Minhui Chen, Mark J. Bucsek, Elizabeth A. Repasky and Bonnie L. Hylander*

Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States

An immune response must be tightly controlled so that it will be commensurate with the level of response needed to protect the organism without damaging normal tissue. The roles of cytokines and chemokines in orchestrating these processes are well known, but although stress has long been thought to also affect immune responses, the underlying mechanisms were not as well understood. Recently, the role of nerves and, specifically, the sympathetic nervous system, in regulating immune responses is being revealed. Generally, an acute stress response is beneficial but chronic stress is detrimental because it suppresses the activities of effector immune cells while increasing the activities of immunosuppressive cells. In this review, we first discuss the underlying biology of adrenergic signaling in cells of both the innate and adaptive immune system. We then focus on the effects of chronic adrenergic stress in promoting tumor growth, giving examples of effects on tumor cells and immune cells, explaining the methods commonly used to induce stress in preclinical mouse models. We highlight how this relates to our observations that mandated housing conditions impose baseline chronic stress on mouse models, which is sufficient to cause chronic immunosuppression. This problem is not commonly recognized, but it has been shown to impact conclusions of several studies of mouse physiology and mouse models of disease. Moreover, the fact that preclinical mouse models are chronically immunosuppressed has critical ramifications for analysis of any experiments with an immune component. Our group has found that reducing adrenergic stress by housing mice at thermoneutrality or treating mice housed at cooler temperatures with β-blockers reverses immunosuppression and significantly improves responses to checkpoint inhibitor immunotherapy. These observations are clinically relevant because there are numerous retrospective epidemiological studies concluding that cancer patients who were taking β-blockers have better outcomes. Clinical trials testing whether β-blockers can be repurposed to improve the efficacy of traditional and immunotherapies in patients are on the horizon.

Keywords: adrenergic, norepinephrine, antitumor immune response, temperature, stress, β-blocker

INTRODUCTION

Psychosocial and physical stresses have long been believed to negatively affect health and reduce our resistance to immune-mediated diseases (including cancer), but the mechanisms have been poorly understood (1, 2). A comprehensive review of early work on the effects of stress on tumor growth in animal models highlights the dichotomous results between viral tumors which grow...
faster with stress and non-viral/chemically induced tumors which grow more slowly during the stress period (3). In the last decade or so, however, we are beginning to understand the myriad mechanisms by which chronic adrenergic stress molds the immune response and promotes tumor growth (2-9). In this brief review, we will first give examples of how adrenergic signaling impacts immune cells and then how it affects tumor growth. We then summarize how preclinical mouse models are used to study the effects of different stress types on tumor growth, survival, and metastasis, highlighting the idea that tumors attract their own innervation in a process akin to angiogenesis. We emphasize the potential ramifications of the baseline cold stress which is imposed on mice by sub-thermoneutral housing and how this impacts our understanding of the capabilities of the endogenous immune response. In addition, in light of recent excitement about the potential of new immunotherapies to treat cancer, we discuss how adrenergic suppression of the antitumor immune response is a targetable checkpoint which may be blocked to increase the efficacy of immunotherapy. Finally, we summarize retrospective clinical epidemiological studies that support the idea of “repurposing” β-blockers for use in oncology.

NEURAL REGULATION OF THE IMMUNE RESPONSE

Stress can impact the immune response through two major neural pathways, the hypothalamic/pituitary/adrenal (HPA) axis and the sympathetic nervous system (SNS); we have recently reviewed these pathways in depth (10). While stimulation of the HPA axis results in the release of glucocorticoids from the adrenal cortex, the SNS innervates the adrenal medulla and stimulates release of the catecholamine neurotransmitters, epinephrine (Epi) and, to a lesser extent, norepinephrine (NE) (11). Perhaps more importantly for the purpose of this review, NE is also released by postganglionic sympathetic neurons which densely innervate both primary and secondary lymphoid organs (12-15) as well as essentially all other organs. Adrenergic receptors (ARs) for NE and Epi are located on the surface of most cells, including immune cells, and thus in addition to the regulatory influences of chemokines and cytokines, NE released from sympathetic nerve endings also plays a critical role in regulating immune cells. In fact, we are now realizing that neural reflexes may reach immune cells in a fraction of the time (milliseconds) that it takes chemokines and cytokines to circulate and have an effect on these cells (16). While activation of the SNS in response to acute stress such as exercise or injury promotes a rapid immune response (17), chronic ongoing stress often is immunosuppressive (18). As discussed below in the Section “Modeling the Tumor-Promoting Effects of Adrenergic Stress/Signaling in Mice”, suppression of the antitumor immune response is one of the consequences of this chronic stress.

Adrenergic receptors are a class of G protein-coupled receptors and are subdivided into two types (α and β) based on their structure, pharmacology, and signaling mechanisms, and these include several subtypes (19). Although there are many studies showing that both α- and β-ARs are expressed by innate immune cells, including neutrophils (20, 21), monocytes (22-24), macrophages (22, 24-26), mature DC (22), NK cells (27-33), and hematopoietic stem cells and progenitors (34), β2-ARs are the most highly expressed subtype on both innate and adaptive immune cells. T and B cells exclusively express β2-AR (35-37); this is also true for hematopoietic stem cells and progenitors (34). Consequently, β2-ARs are regarded as the main mediators of the immune effects of catecholamines (8). Activation of these receptors activates adenylate cyclase to increase intracellular cAMP which in turn activates PKA which ultimately activates downstream transcription factors (2, 35, 36, 38-40). The details of this signaling pathway have recently been reviewed for both immune cells (41) and cancer cells (9).

Adrenergic Regulation of Innate Immunity

That activity of innate immune cells is regulated by activation of ARs has been clearly demonstrated. Adrenergic signaling affects macrophage polarization and cytokine production. β-AR signaling promotes macrophage differentiations toward an M2 phenotype which produces anti-inflammatory cytokines (42-45). In one study, gut macrophages in the muscularis mucosa, which are in close proximity to the autonomic myenteric plexus, differentially expressed the β2-AR, which mediated alternative activation of these macrophages, resulting in an M2 anti-inflammatory and tissue-protective profile (46). Both in vitro and in vivo studies support the conclusion that at least one way in which β-adrenergic signaling can promote breast cancer progression is by polarizing macrophages toward an M2 phenotype (42, 43). Moreover, in response to LPS stimulation, human monocyte-derived macrophages produce reduced amounts of the inflammatory cytokines TNF-α, IL-1β, CCL2, CCL3, and CCL4 (47-49) and decrease IL-27 secretion in response to acute inflammation (50) while, at the same time, increasing production of the anti-inflammatory cytokines IL-4, IL-10, and IL-13 production (44, 50). In contrast to the effects of β-AR signaling in macrophage, α-AR signaling promotes secretion of pro-inflammatory cytokines (24, 51).

Adrenergic signaling has been shown to impact DCs by impairing their maturation, cytokine production, and antigen presentation. Studies have shown that β2-AR activation prevents differentiation of monocytes into DCs (52) and enhances production of the anti-inflammatory cytokines IL-6, IL-10, and IL-33 while decreasing IL-12 and TNF-α production (53-58) by inhibition of NF-κB and AP-1 (54). In addition to altering cytokine production, Epi has also been shown to activate β1-AR/ arrestin2-PI3K-MMP9/CCR7 signaling to inhibit migration of human DCs (59) which could impair migration to lymph nodes. Pretreating bone marrow derived DCs (BMDC) with β2-AR agonists before adoptive transfer reduces migration and responses to chemokines. Both in vitro and in vivo studies show that α2-AR suppresses DC migration by inhibiting type IV collagenase/gelatinase activity (60). The primary function of DCs, antigen presentation, is impaired by treating epidermal Langerhans cells with catecholamines, and this effect is blocked by using a β2-AR antagonist (61). In addition, cross-presentation of proteins by DCs is impaired by activation of β2-AR signaling, which
in turn decreases CD8+ T cell proliferation and IL-2 production (62). Our lab has also found that adrenergic stress impacts the phenotype and function of DCs (63) in ways that could suppress their function.

Several studies have demonstrated that chronic adrenergic signaling can suppress NK cell activity. In a restraint stress mouse model, the number of NK cells is reduced in the intra-parenchymal region of the lung and circulation (64). Another study showed that activation of β-ARs reduces the activity (65) of murine NK cells and leads to an increase in tumor metastasis. Interestingly, the two arms of the stress response can cooperate to regulate immune cells. De Lorenzo et al. found that during sleep deprivation, glucocorticoids increase expression of β2-AR in NK cells resulting in reduction of NK cell numbers and cytotoxicity (66). In contrast to the effects observed in these models of chronic stress, some studies have concluded that stress can increase NK cell activation and function. In one such study, six episodes of social disruption increased NK cell activity (67).

In addition, voluntary exercise reduces the incidence and growth of breast cancer and this effect is mediated by catecholamine induced plasma IL-6, which in this case mobilizes NK cells (17). Enriching the housing environment for mice also increases induced plasma IL-6, which in this case mobilizes NK cells (17).

In addition, there are many reports investigating the regulation of other innate immune cells by adrenergic signaling. For example, a β2-AR agonist was able to prevent eosinophil function which are induced by exposure to IL-5, LTD4, or IP-10 and blocking β2-AR signaling promotes eosinophils to secrete IL-5 (72). Adrenergic signaling decreases production by DCs. A study in stressed mice showed that β-AR signaling promotes negative selection in the thymus through the p38 mitogen-activated protein kinase pathway, resulting in decreased numbers of thymocytes (71). In addition, exposure to chronic unpredictable stress reduces the number of double negative thymocytes (72).

Adrenergic Regulation of Adaptive Immunity

Norepinephrine also activates ARs on lymphocytes to regulate the differentiation, trafficking/migration, and effector functions of all lymphocyte subpopulations (11). Adrenergic signaling impacts T-cells by directly regulating thymocytes and inhibiting activation, differentiation, and effector function of T-cells directly or indirectly by inhibiting T-cell activating cytokine production by DCs. A study in stressed mice showed that β-AR signaling increases expression of IL-2, IFN-γ, and proliferation of CD4+ T-cell through many mechanisms. β2-AR signaling inhibits cytokines by inhibiting calcineurin in a PKA dependent manner (73). IFN-γ production by CD4+ T-cells can also be affected indirectly by inhibition of cytokine production by DCs. Adrenergic signaling also regulates Th1 and Th2 differentiation (34). Naïve CD4+ T-cells or activated Th1 cells express a detectable level of the β2-AR, while Th2 cells do not, due to differences in histone and DNA modifications within the β2-AR proximal promoter (22, 74). Therefore, Th1 cells can be suppressed by adrenergic signals and β2-AR activation has been found to be involved in directing CD4+ T-cell polarization toward a Th2 phenotype (75). The impact of β2-AR signaling on CD8+ T-cells depends on the stage of differentiation. Memory and effector CD8+ T-cells have significantly higher expression of β2-ARs than naïve T-cells and β2-AR signaling reduces IL-2 and IFN-γ production by memory CD8+ T-cells upon restimulation (76). IL-2 increases β2-AR expression on effector CD8+ T-cells; however, β2-AR signaling suppresses IL-2 production by CD8+ T-cells, which forms a negative-feedback loop in regulating CD8+ T-cell activation and function (77). By contrast, while β2-AR signaling suppresses CD8+ effector T-cell function, β2-AR signaling in regulatory T-cells increases their suppressor activity by increasing expression of the checkpoint molecule CTLA-4 and promotes inducible Tregs by inducing Foxp3 expression in T-cells (55).

Suppression of immune cells by chronic adrenergic stress has long-term negative implications for disease progression and has been well studied in the context of both infectious diseases and autoimmune diseases. β2-AR signaling impairs CD8+ T-cell-mediated antiviral responses to influenza in vivo and blocking the β2-AR with Nadolol enabled development of a robust antiviral response (78). Similarly, β2-AR signaling reduced the CD8+ T-cell response to the vesicular stomatitis virus (79).

NEURAL REGULATION OF TUMOR GROWTH

The early observations of Levi Montalcini and collaborators first clearly demonstrated that tumor cells secrete nerve growth factors and can induce neural outgrowth from both sensory and sympathetic ganglia (82). As evidence of the tumor promoting effects of adrenergic signaling accumulated, Entschladen and colleagues hypothesized that in a process analogous to angiogenesis and lymphangiogenesis, tumors might secrete neurotrophic factors to attract their own innervation (83). But it was the elegant study of Magnon et al. (84) that clearly demonstrated both the ability of a developing tumor to attract autonomic innervation and the critical role such innervation plays in development and progression of a tumor. Using an orthotopic xenograft model (PC-3 prostate cells), they showed that the developing tumor attracted new autonomic innervation and that if they severed the hypogastric nerves or chemically sympathectomized the mice, tumor growth was significantly inhibited. Furthermore, they showed that parasympathetic nerves promoted the later stages of invasion and metastasis. Others have shown that NE levels...
in tumors are elevated by stress that activates the SNS and that NE is produced locally within tumors (as evidenced by tyrosine hydroxylase positive cells) (81, 85–88).

In the last decade or so there has been a growing effort to understand how adrenergic signaling promotes tumor growth and we now know that β-AR signaling acts through multiple mechanisms (Figure 1). ARs are expressed by multiple cell types found in the tumor microenvironment and, therefore, the effects of adrenergic signaling that support tumor survival, growth, and metastasis are complex.

Direct effects include promoting tumorigenesis, tumor cell proliferation, antiapoptotic mechanisms, and promoting metastasis by inducing epithelial to mesenchymal transformation (EMT), motility and invasion. β-Adrenergic signaling activates p53 degradation and DNA damage through the β-AR/ARRB1/PKA pathway (89–91) and activation of oncogenes, such as Src and Her2 (92) and may promote tumorigenesis. In addition, increased psychological stress is associated with decreased telomere length (93), which is associated with increased cancer risk (94). Adrenergic signaling promotes tumor cell proliferation both in vitro and in vivo (95–101), while blocking adrenergic signaling leads to G1/S phase cell cycle arrest and apoptosis (102, 103). Antiapoptotic mechanisms are upregulated in tumor cells both in vitro and in mouse xenografts (84, 85, 104–106). Our lab found that adrenergic signaling increases expression of the antiapoptotic proteins BAD, BCL-2, and MCP-1 in tumors and blocking adrenergic signaling significantly reduces antiapoptotic protein expression and tumor growth (85). In addition, in vitro, NE activates the TGF-β pathway in treated cancer cells enhancing migration and invasion (107, 108). Mesenchymal markers such as α-SMA, vimentin, and snail are also increased by β-adrenergic signaling (109, 110). More recently, analysis of exosomes isolated from ovarian patients with high levels of adrenergic pathway activation (associated with low social support) shows upregulation of mesenchymal-characteristic gene transcripts and downregulation of epithelial-characteristic gene transcripts, and this is mediated by the ADRB/cAMP/PKA pathway (111). Adrenergic signaling plays a vital role in promoting metastasis (112–122) and could directly induce invasive genes such as MMPs by tumor cells (123) and indirectly by causing cancer-associated fibroblasts to produce high levels of collagen and extracellular matrix components, which facilitate tumor invasion and dissemination (124).

Adrenergic signaling also affects other cells in the tumor microenvironment, which in turn support tumor growth, survival and metastasis. Studies show that adrenergic signaling promotes angiogenesis through increasing VEGF, IL-8, IL-6, PEG2 expression in tumor cells (87, 119, 125–130), and decreasing expression of TSP1, a potent angiogenesis inhibitor (129). A recent study from Zahalka et al. demonstrates that adrenergic signaling also directly alters the metabolism of endothelial cells in the TME, leading to increased angiogenesis (131). In addition, studies demonstrate that adrenergic signaling promotes lymphangiogenesis by inducing VEGF production by tumor cells and/or macrophages (112, 132). Formation of a pre-metastatic niche in the lung is induced by adrenergic signaling in monocyte/macrophage cells in a breast cancer model (133). In another study, stimulation of bone marrow stromal cells by adrenergic signaling increases breast cancer bone colonization (115). Finally, it is becoming clear that the immunosuppressive effects of adrenergic signaling that have been seen in infection models (78, 79) are also playing a major role in suppressing the antitumor immune response. This inhibits tumor infiltration and function of cytotoxic T-cells (134–136) and promotes infiltration of immunosuppressive cells such as MDSC and Tregs (134, 136–139).

**MODELING THE TUMOR-PROMOTING EFFECTS OF ADRENERGIC STRESS/ SIGNALING IN MICE**

Although the concept of stress is generally understood, it is challenging to define. The original concept of stress, as proposed by Selye, was the response of an organism to a stimulus that challenged its well-being and he called this the General Adaptation Syndrome (140). Briefly, he proposed that an organism had the same response to many different noxious stimuli (swelling of the adrenal cortex, atrophy of the thymus, gastric ulcers) and that people suffering from various diseases had the same symptoms or syndrome. Eventually, he coined the term “stressor” to refer to the stimulus and the “stress response” to refer to the reaction. Stressors can be psychological (such as anxiety, fear, depression), physical (such as injury, surgery), or physiological (environmental factors including temperature) and exposure to stressors.
can be either acute (a single short-term exposure—minutes to hours) or chronic (long term, ongoing, or repeated). In general, an acute stress such as an injury leads to a beneficial response including activation of immune cells, whereas chronic exposure is most often deleterious and immunosuppressive (141). Dhabhar (18) has discussed the idea of categorizing stress as “protective, pathological, or regulatory” depending on their effects on overall health.

There is a general view that stress is detrimental to health and in ovarian carcinoma patients with little social support, it has been shown that the stress of social isolation elevates tumor and ascites NE while Epinephrine was undetectable; this elevated NE correlates with more severe disease stages (86). To study how stress impacts tumor growth in preclinical models, protocols for inducing stress in mice have been developed (Table 1). It is important to point out that the same method can be used to induce both acute and

| Reference            | Tumor model                        | Effects on tumor growth                                                                 | Mechanisms                                                                 |
|----------------------|------------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| **Psychological stress—restraint: confinement, unable to move freely** |                                    |                                                                                        |                                                                           |
| Kim-Fuchs et al. (123)| Human pancreatic cancer/nude mice  | Increases tumor growth and dissemination of tumor cells to adjacent pancreas and liver | β-Adrenergic receptor (AR) signaling induces expression of tumor invasion genes and matrix metalloproteases, MMP2 and MMP9 |
| Le et al. (132)       | Human breast cancer/nude mice       | Promotes lymphangiogenesis and tumor cell dissemination and metastasis                  | β-AR induces tumor-associated macrophages producing inflammatory molecules such as PGE2, which in turn induce tumor cells to produce VEGFC promoting lymphatic remodeling |
| Hulsurkar et al. (129)| Human prostate cancer/NOD/SCID       | Promotes tumor growth                                                                  | β-AR signaling activates CREB and induces HDAC2 expression by binding to its promoter. HDAC2 repression of TSP1 expression, promotes angiogenesis and prostate cancer progression |
| Hassan et al. (104)   | Prostate cancer/nude mice Hi-Myc mice (and fear) | Antiapoptotic effect on tumor                                                          | Increased tumor catecholamine levels, which activates the epinephrine/ADR2/PKA/BAD antiapoptotic signaling pathway |
| Nagaraja et al. (119) | Human ovarian cancer injected        | Increases tumor production of inflammatory prostaglandins and tumor metastasis         | Increases prostaglandin E2(PGE2) synthesis via ADRB2–NF-κB–PTGS2 axis       |
| Nagaraja et al. (124) | Human ovarian cancer/nude mice       | Increases tumor growth                                                                  | NE drives cancer-associated fibroblast (CAF) phenotype via ADRB2/CREB/INHBA axis. CAFs produce high levels of collagen and extracellular matrix components |
| Lin et al. (143)      | Human colon cancer/nude mice        | Increases tumor weight                                                                 | Increases plasma catecholamine; induces hyper-phosphorylation of ERK1/2, which drives cell proliferation |

| **Psychological stress—social isolation: individual housing** |                                    |                                                                                        |                                                                           |
| Thaker et al. (88)    | Human ovarian cancer/nude mice (and restraint stress) | Increases tumor burden; more invasive growth of tumor | Increases size of adrenal glands; higher levels of tissue catecholamine; enhances tumor angiogenesis and enhances tumor expression of VEGF, MMP2, and MMP9 by activation of ADRB2/cAMP/PKA pathway |
| Madden et al. (144)   | Human breast cancer/SCID             | Increases tumor growth                                                                  | Increases tumor F4/80+ and CD11b+Gr-1+ macrophage populations              |
| Chen et al. (133)     | Murine breast cancer i.v./BALB/c; MMTV-PyMT-C57Bl/6 (and chronic unpredictable stressors) | Promotes breast cancer metastasis to lung                                              | β-AR signaling induces expression of CCL2 in pulmonary stromal cells and CCR2 in monocytes/macrophages; increases recruitment and infiltration of macrophages into the pre-metastatic lung |
| Qin et al. (42)       | Murine mammary cancer/BALB/c         | Increases tumor growth                                                                  | Increases serum catecholamine levels; increases migration of 4T1 cells in vitro; polarizes macrophage to M2 phenotype |

| **Psychological stress: acoustic** |                                    |                                                                                        |                                                                           |
| Hou et al. (145)      | Murine colon cancer/BALB/c           | Promotes tumor progression                                                             | Increases serum catecholamine and corticosterone; change Th1 and Th2 cytokines, and shift from Th1 to Th2 response in both circulation and tumor |
| Partecke et al. (146) | Murine pancreatic cancer/C57BL/6     | Increases tumor growth and reduces survival                                            | Increases behave stress; increases serum corticosterone and adrenal tyrosine hydroxylase; reduces Th1 cytokines; increases infiltration of Treg cells in tumor; increases VEGF and TGF-β with greater microvessel densities; increases MMP9 expression |

(Continued)
chronic stress and these are distinguished by the duration of exposure. A good example of this is a study that used restraint stress to compare changes in the hippocampal transcriptome following acute vs. chronic stress by looking at samples taken after 1, 8, or 13 days of stress exposure (142).

To model psychological stress, mice have most often been subjected to social isolation or restraint stress. Over 10 years ago, using a mouse xenograft model of ovarian cancer, Thaker’s group showed that restraint stress resulted in significant elevation of NE (255–358%) and corticosterone (488–789%) in organs adjacent to the peritoneal cavity in tumor-bearing mice. Tumor growth and metastasis were also significantly increased 1×/week. Normally housed at four to five per cage; in fact, special enrichment materials are required. In addition to social isolation and found enlargement of the adrenal glands in response to psychosocial stressors. Qin et al. found that Epi was elevated and breast cancer progression was promoted in association with an M2 skewed macrophage population in a social isolation model; however, NE levels were not reported (42). Partecke et al. found that in response to a combination of acoustic and chronic stress, animals’ measures of behavioral stress as well as levels of stress hormones (steroids and adrenal tyrosine hydroxylase, the rate limiting enzyme in NE synthesis) were significantly elevated and furthermore, that orthotopic, syngeneic pancreatic tumors grew faster in these mice and there were indications that their immune response was suppressed,

### TABLE 1 | Continued

| Reference | Tumor model | Effects on tumor growth | Mechanisms |
|-----------|-------------|-------------------------|------------|
| Physical/psychological stress: surgery |
| Lee et al. (147) | Human ovarian cancer/ nude mice | Increases tumor growth | Increases angio genesis; increases serum G-CSF, IL-1α, IL-6, and IL-15 concentrations |
| Eng et al. (85) | Human pancreatic cancer/SCID Murine pancreatic cancer/C57BL/6 | Increases tumor ant apoptosis, resistance to chemotherapy, tumor growth | Increases tumor catecholamines; increases antia apoptotic proteins expression |
| Bucsek et al. (134) | Murine mammary cancer/BALB/c Murine melanoma/C57BL/6 | Increases tumor growth | Increases serum catecholamine; decreases tumor infiltrating CD8+ T cells and CD4+ T cells |
| Kokolus et al. (136) | Murine mammary cancer, colon cancer/BALB/c Murine melanoma/C57BL/6 | Increases tumor growth | Decreases tumor infiltrating CD8+ T cells, CD4+ T cells; increases immunosuppressive cells |
| Acute stress: restraint |
| Dhabhar (18) | Ultraviolet-B (UV) induced squamous cell carcinoma | Decreases tumor incidence and fewer tumors | Increases cutaneous-T-cell-attracting-chemokine (CTACK)/ CCL27, RANTES, IL-12, and IFN-γ gene expression; increases skin infiltrating T cell numbers |
| Exercise stress: voluntary running |
| Pedersen et al. (17) | Melanoma or lung cancer/C57BL/6 DEN-induced liver tumors/NMRI male mice | Reduces tumor incidence and growth | Increases serum catecholamine; increases plasma IL-6; mobilizes NK cells |
| Dethlefsen et al. (148) | Stage I/II breast cancer patient; human breast cancer/female NMRI-Foxn1nu mice | Reduces tumor growth | Exercise-conditioned human serum decreases breast cancer cell viability and tumorigenic potential; catecholamine induces Hippo tumor suppressor signaling pathway, which inhibits tumor growth |
| Environmental enrichment* |
| Song et al. (69) | Murine pancreatic cancer and lung cancer/C57BL/6Beige mice/Rag1−/− mice | Decreases tumor growth and benefit is lost if mice receive a β-blocker or chemical sympathectomy | β-Adrenergic signaling enhances NK cell-mediated antitumor immune responses; increases expression of CCR5 and NKG2D in NK cells; and increases tumor infiltration of NK cells |

*Chronic unpredictable stressors include cage tilt, isolation, crowding, rapid light–dark changes, damp bedding, and overnight illumination.

*Environment enrichment: mice housed 12/cage in large cages with running wheels, tunnels, wooden toys, small huts, and nesting materials, which were moved 2x/week and changed 1x/week.
with a trend toward fewer CD4 and increased intratumoral Tregs present (146). Treatment of these mice with propranolol reduced tumor growth and improved overall survival (OS). These studies and several others (see Table 1) demonstrate that psychosocial stress promotes tumor growth through various mechanisms and that adrenergic signaling can be blocked by administration of β-AR or specific β2-AR antagonists.

In laboratory studies, the effects of physical/physiological environmental stressors on catecholamine levels and tumor growth have not been as well studied as the effects of psychological stresses, but environmental factors have great capacity to induce a stress response and alter internal metabolism and physiology (149). Our lab has recently defined a role for chronic mild cold stress in promoting tumor growth. This environmental stressor is universally imposed on mice as a result of mandated, cool ambient housing temperatures (150), and the impact of this cold stress on the modeling of several non-tumor mouse models of disease has been recently reviewed (151–153).

The increasing awareness of this problem is reflected in several additional publications over the last 2–3 years reporting on how ambient housing temperatures affect disease outcomes in atherosclerosis (154–157), Alzheimer’s (158), monocyte mobilization into the blood (159), and obesity (160–162). Newer reviews have also drawn attention to this situation (163, 164). We first reported the unexpected discovery that when mice are housed at thermoneutrality (30°C), tumor growth is significantly inhibited in comparison to mice housed at standard temperatures (22°C) even though mice under both conditions maintain a normal core body temperature of 37°C (136). We also demonstrated that this difference in tumor growth was dependent on the adaptive immune response which was significantly suppressed when mice were housed at 22°C. Furthermore, we found that although the effects of cold stress are commonly studied by exposing mice to 4°C, just housing mice at the sub-thermoneutral 22°C was sufficient to cause chronic cold stress and significant elevation of both plasma and tumor NE levels (85, 134). Thus we found that even what was considered mild cold stress at 22°C, is biologically sufficient to induce SNS activation to produce NE and drive non-shivering thermogenesis to maintain a normal body temperature. Furthermore, we have shown that chronic adrenergic signaling in mice housed at 22°C promotes tumor growth in two different ways, both by induction of antiapoptotic signaling molecules and resistance to cytotoxic therapies in tumor cells (85) and by profound immunosuppression of the antitumor immune response which is associated with increases in immunosuppressive cell populations and inhibition of CD8+ T-cell effector phenotypes (134). Therefore, not only are the tumor cells more resistant to being killed, but the ability of the immune cells to kill tumor cells is much less robust when NE levels are increased by baseline housing stress; both of these situations are reversed by administration of the β-blocker propranolol. Interestingly, the recent studies of Wrobel et al. (135) agree with our findings; this group administered propranolol to MT/Ret mice and found inhibition of tumor development, increased CD8+ T-cells in the tumors, and decreased MDSC. However, these authors did not associate this baseline stress with housing temperature and the temperature at which their mice were housed was not reported.

We are particularly concerned about this immunosuppression by baseline adrenergic stress in experimental mice because both the long-term outcome of traditional therapies (165–170) and immunotherapies (171) depend on the development of a robust antitumor immune response. We tested whether the efficacy of immunotherapy, specifically checkpoint inhibitor therapies, was limited by adrenergic stress. In mouse models

![FIGURE 2](image-url)
of melanoma and breast cancer, we used three separate approaches: housing mice at 30°C, treating mice housed at 22°C with β-blockers, or testing anti-PD-1 in ADRB2−/− mice at 22°C and asked how this impacted in efficacy of anti-PD-1. In each case, it is clear that adrenergic signaling reduces responses to checkpoint inhibitor therapy and the efficacy is significantly improved by reducing this stress.

Taken together, it is clear that the majority of studies on the effects of stress are performed at 22°C when the “control” mice are already "stressed" in comparison to the relatively reduced levels they would be experiencing at 30°C (Figure 2). Therefore, restraint stress or other forms of psychosocial stress are imposed on already stressed mice, so that measures of tumor growth, response to therapy or the capabilities of the antitumor immune response in the controls are somewhat compromised. In the future, it will be important to determine if, and/or how, baseline cold stress may be affecting the results of these stress experiments. Although due to the thermal comfort requirements of personnel, it seems unlikely that the ambient temperatures in animal facilities will be changed to 30°C, it may be possible to reduce cold stress in experimental animals by providing nesting materials or constructing special cages in which mice can behaviorally regulate their thermal comfort (172–174).

### Table 2 | A summary of retrospective studies assessing the beneficial effects of β-blockers, including Propranolol, in patients with different cancers who were also taking β-blockers.

| Reference | Cancer type | Patients (numbers) | Survival | OR/HR | 95% CI | P | Therapeutic effect |
|-----------------|--------------|-------------------|----------|--------|--------|---|-------------------|
| **β-Blockers (other than propranolol)** | | | | | | | |
| Grytli et al. (188) | Prostate cancer | 263 | HR: 0.14 | 0.02–0.85 | 0.032 | Reduced prostate cancer-specific mortality |
| Grytli et al. (189) | Prostate cancer | 3,561 | ASR: 0.79 | 0.68–0.91 | 0.001 | Reduced prostate cancer-specific mortality |
| Kaapu et al. (190) | Prostate cancer | 24,657 | OR: 0.73 | 0.56–0.96 | 0.038 | Decreased risk of advanced prostate cancer |
| De Giorgi et al. (191) | Thick melanoma | 121 | | | | | Reduce risk of progression of thick malignant melanoma |
| Lemeshow et al. (192) | Malignant melanoma | 4,179 | HR: 0.87 | 0.64–1.20 | 0.038 | Increase survival time of patients with melanoma |
| Diaz et al. (193) | Epithelial ovarian cancer | 248 | PFS OS | 0.56 | 0.05 | Reduce chance of death |
| Wang et al. (194) | Non-small-cell lung cancer | 722 | DMFS DFS OS | 0.67 | 0.01 | Improved DMFS, DFS, and OS |
| Botteri et al. (195) | Triple-negative breast cancer | 800 | HR: 0.42 | 0.18–0.97 | 0.027 | Significantly decreased risk of breast cancer-related recurrence, metastasis, and breast cancer death |
| Melhem-Bertrandt et al. (196) | Triple-negative breast cancer | 1,413 | RFS | 0.30 | 0.1–0.87 | 0.027 | Improve relapse-free survival in all patients with breast cancer and in patients with triple-negative breast cancer |
| Powe et al. (197) | Breast cancer | 466 | HR: 0.291 | 0.119–0.715 | 0.007 | Significantly reduces distant metastases, cancer recurrence, and cancer-specific mortality in breast cancer patients |
| Jansen et al. (198) | Colorectal cancer | 1,975 | HR: 0.50 | 0.33–0.78 | 0.038 | Association with longer survival |
| Monami et al. (199) | Cancer | 1,340 | HR: 0.33 | 0.019 | Reduce cancer risk |
| Lin et al. (200) | Cancer | 6,771 | HR: 0.74 | 0.63–0.87 | <0.001 | Reduced upper gastrointestinal tract and lung cancer risk |
| **Propranolol** | | | | | | | |
| Choy et al. (201) | Triple-negative breast cancer | 1,029 | HR: 0.51 | 0.23–0.97 | 0.041 | Decreased establishment of brain metastasis |
| Barron et al. (202) | Breast cancer | 5,801 | HR: 0.19 | 0.06–0.60 | 0.038 | Reduce breast cancer progression and mortality |
| Nkontchou et al. (203) | Hepatocellular carcinoma | 291 | HR: 0.25 | 0.09–0.65 | 0.004 | Decrease hepatocellular carcinoma occurrence |
| Chang et al. (204) | Head and neck | 24,238 | | | | | Reduce cancer risk |

ASR, adjusted hazard ratio; DFS, disease-free survival; DMFS, distant metastasis-free survival; HR, hazard ratio; OR, odds ratio; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; 95% CI, 95% confidence interval.

β-Blockers other than propranolol include pindolol, propranolol, timolol, carvedilol, labetalol, nadolol, oxprenolol, alpenrolol, sotalol, acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, celiprolol, esmolol, carteolol, penbutolol, and celiprolol.
CLINICAL RELEVANCE OF PRECLINICAL FINDINGS

How do these findings relate to patients? Studies have demonstrated that several types of patient tumors express ARs including pediatric (175, 176), pancreatic (103), lung (177), melanoma (178), and prostate (179) cancers. More provocatively, as it became apparent that blockade of adrenergic signaling could inhibit tumor growth in preclinical models, researchers looked for evidence of benefit in patients. Several retrospective epidemiological studies have supported the conclusion that patients who are taking β-AR antagonists (“β-blockers”) and receiving conventional therapies have better outcomes in terms of both progression-free survival and OS than those who are not (Table 2). It should be noted, however, that there are other analyses that failed to identify any benefit of β-blockers (180–186). There are several potential reasons for why some studies show that cancer patients benefit from taking β-blockers while other studies conclude there is no benefit. One important reason is that the type of β-blocker being taken by the patient likely influences the patient’s response as well as the overall outcome of the study. There are studies showing that patients taking non-selective β-blockers (blockade of β1 and β2) had improved OS compared with patients taking β1-specific blockers which are the most commonly prescribed β-blockers (180, 183, 184, 187). The heterogeneity of ARs expressed by the tumors themselves may also account for the different responses in cancer patients (180, 184). Besides the type of β-blocker, it is possible that the dosage needed to elicit a favorable antitumor effect is higher than the normal prescription dose for treating cardiovascular diseases (182, 185). In addition, the patient parameters are variable among the studies. Although the most important potential confounders such as sex, stage, treatment were usually adjusted for, there are others, such as socioeconomic status which is proven to be associated with cancer progression, which were not taken into consideration (182, 185). The timing of β-blocker exposure is different between studies. Some studies recruited patients already taking β-blockers before cancer diagnosis, while some studies investigated patients who began taking β-blockers after cancer diagnosis (180, 181, 183, 184). In addition, there are limited records showing whether patients complied with the prescriptions (182, 185). The study design may also influence the result. Some studies used all-cause of mortality as the endpoint, which makes it hard to study the relationship of β-blocker usage and cancer-specific mortality (183). In other studies, patients taking β-blockers who died within 3 months after cancer diagnosis were still included, which is thought to be too short an interval to assess benefit (181–184).

To date, there has been a single report of a prospective study treating melanoma patients with propranolol. In this study, De Giorgi and colleagues offered patients the choice of “off-label” treatment with propranolol and found an 80% risk reduction for recurrence for the 19 of 53 patients who chose to receive it (205). Ultimately, the ability of β-blockers to support the development of an antitumor immune response and to improve the efficacy of traditional and immunotherapies will have been determined in blinded, prospective clinical trials, but the results of this study in melanoma lend support for the “repurposing” of β-blockers in oncology.

β-Blockers have been used extensively in the clinic to treat patients with hypertension, angina and anxiety. In general, β-blockers have a good toxicity profile and are well tolerated (206); common side effects include nausea, vomiting, diarrhea, insomnia, weakness and fatigue. However, the safety of using of β-blockers in cancer patients needs to be considered. Although most cancer patients do not have hypertension and/or angina, they do often have increased levels of adrenergic stress and so in that way may be considered to have abnormal adrenergic signaling. In several studies in which cancer patients were taking β-blockers as an off-label treatment, either no drug related adverse effects were recorded (205, 207) or small number of patients had minor side effects which did not require discontinuation (203, 208, 209). However, an understanding of the comparative safety of β-blockers in combination with other cancer therapies remains to be evaluated in the context of clinical trials.

CONCLUSION

Recently developed immunotherapies are showing great promise in cancer treatment, yet many tumor types are not responding and even in sensitive tumors such as melanoma and lung cancer, the majority of patients are not benefitting. Therefore, developing new strategies for improving the therapeutic efficacy of cancer immunotherapies is critical. Immunotherapies and traditional therapies that have an immune-mediated component depend on the development of a robust antitumor immune response, but immunosuppressive factors often limit this. Therefore, a promising strategy to improve response to immunotherapy is to develop additional approaches to reverse immunosuppression that can be used in combination therapies.

A newly identified mechanism of immunosuppression is by stress-induced sympathetic adrenergic signaling, which suppresses many aspects of the immune system including development, differentiation, activation, and function of many types of immune cells. Adrenergic signaling has been shown to inhibit immune responses in both autoimmune diseases and infection models. Sympathetic neurons innervate both primary and secondary lymphoid organs supporting the idea that adrenergic signaling can impact immune cells locally. Recently, it has become clear that adrenergic signaling also affects tumor progression. By using mouse models of both psychosocial and physical stress stress-induced adrenergic signaling was found to be tumor-promoting in many types of cancers. The accumulated evidence demonstrates that adrenergic stress regulates tumor growth directly through multiple mechanisms, including development, proliferation, and protection of tumor cells from treatments. Although less well studied, recent findings show that adrenergic signaling also impacts tumor growth indirectly by regulating antitumor immunity. Our lab recently demonstrated that chronic mild cold stress induces SNS activation which promotes tumor growth; blocking this stress by either housing mice at thermoneutral temperature or adding β-blockers slows
tumor growth. These effects were found to be mediated by CD8+ T-cells. In addition, combining a pan-β-blocker with an immune checkpoint inhibitor (anti-PD-1) significantly increased the therapeutic efficacy of anti-PD-1. Because cancer patients who were already taking β-blockers were found to have better outcomes in several retrospective studies, the preclinical studies provide a rationale for testing this combination in prospective clinical trials. Finally, accumulating evidence shows that external environmental stressors, i.e., housing temperature, creates β lymphocytes. In addition, combining a pan-

AUTHOR CONTRIBUTIONS

GQ, MC, MB, ER, and BH developed the concepts for this review and were involved in identifying the references and writing and editing the manuscript.

FUNDING

This research was supported by The Breast Cancer Coalition of Rochester, NY; The Peter T. Rowley Breast Cancer Research Grant CD28252; The Harry J. Lloyd Charitable Trust; The Roswell Park Alliance Foundation; The National Institute of Health Grant 5-T32CA085183 and used Shared Resources supported by the Roswell Park Cancer Institute's Comprehensive Cancer Center Support Grant CA016056.
on human natural killer (CD16+) cells. J Neuroimmunol (1997) 74:159–64. doi:10.1016/S0165-5728(96)00214-4
32. Benshop RJ, Oostveen FG, Hasenij CJ, Balleux RE. Beta-2-adrenergic stimulation causes detachment of natural killer cells from cultured endothelium. Eur J Immunol (1993) 23:3242–7. doi:10.1002/eji.1802321320
33. Schoedlovski M, Hosh W, Oberbeck R, Benshop RJ, Jacobs R, Raab HR, et al. Catecholamines modulate human NK cell circulation and function via spleen-independent beta-2-adrenergic mechanisms. J Immunol (1996) 156:93–9.
34. Muthu K, Iyer S, He LK, Szilagyi A, Gamelli RL, Shankar R, et al. Murine hematopoietic stem cells and progenitors express adrenergic receptors. J Neuroimmunol (2007) 186:27–36. doi:10.1016/j.jneuroim.2007.02.007
35. Cremaschi GA, Fisher P, Boege F. Beta-adrenoceptor distribution in murine lymphoid cell lines. Immunopharmacology (1991) 22:195–206. doi:10.1016/0162-3109(91)90044-Y
36. Kohm AP, Sanders VM. Suppression of antigen-specific Th2 cell-dependent IgM and IgG1 production following norepinephrine depletion in vivo. J Immunol (1999) 162:5299–308.
37. Van Tits LJ, Michel MC, Grosse-Wilde H, Happel M, Eigler FW, Soliman A, et al. Catecholamines increase lymphocyte beta-2-adrenergic receptors via a beta-2-adrenergic, spleen-dependent process. Am J Physiol (1990) 258: E191–202.
38. Bartik MM, Bauman GP, Brooks WH, Roszman TL. Costimulatory signals modulate the antiproliferative effects of agents that elevate cAMP in T cells. Cell Immunol (1994) 158:116–30. doi:10.1006/cimm.1994.1261
39. Bauman GP, Bartik MM, Brooks WH, Roszman TL. Induction of cAMP-dependent protein kinase (PKA) activity in T cells after stimulation of the prostaglandin E2 or the beta-adrenergic receptors: relationship between PKA activity and inhibition of anti-CD3 monoclonal antibody-induced T cell proliferation. Cell Immunol (1994) 158:182–94. doi:10.1006/cimm.1994.1266
40. Kasprowicz DJ, Kohm AP, Berton MT, Chruscienski AJ, Sharpe A, Sanders VM. Simulation of the B cell receptor, CD66 (B7-2), and the beta-2-adrenergic receptor intrinsically modulates the level of IgG1 and IgG1 produced per B cell. J Immunol (2000) 165:680–90. doi:10.4049/jimmunol.165.2.680
41. Lorton D, Bellinger DL. Molecular mechanisms underlying beta-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells. Int J Mol Sci (2015) 16:5635–65. doi:10.3390/ijms16035635
42. Qin JF, Jin FJ, Li N, Guan HT, Lan L, Ni H, et al. Adrenergic receptor beta2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. BMB Rep (2015) 48:295–300. doi:10.5483/BMBRep.2015.48.5.008
43. Lornet D, Bellinger DL. Molecular mechanisms underlying beta-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells. Int J Mol Sci (2015) 16:5635–65. doi:10.3390/ijms16035635
44. Qin JF, Jin FJ, Li N, Guan HT, Lan L, Ni H, et al. Adrenergic receptor beta2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. BMB Rep (2015) 48:295–300. doi:10.5483/BMBRep.2015.48.5.008
45. Yoon MK, Hwang JH, Suh SH, Kim TY, Go J, Hwang SJ, et al. Beta-Adrenergic receptor-mediated increases inactivation and function of human cord blood-derived dendritic cells by interfering with synthesis and secretion of IL-12 and IL-23. PLoS One (2016) 11:e0153288. doi:10.1371/journal.pone.0153288
46. Takenaka MC, Araujo LP, Maricato JT, Nascimento VM, Guercesi MG, Rezende RM, et al. Norepinephrine controls effector T cell differentiation through beta2-adrenergic receptor-mediated inhibition of NF-kappaB and 1P1 in dendritic cells. J Immunol (2016) 199:6367–44. doi:10.4049/jimmunol.1501206
47. Giordani L, Cuzzolol N, Del Pinto T, Sanchez M, Maccari S, Massimi A, et al. beta2-Agonist clenbuterol hinders human monocyte differentiation into dendritic cells. Exp Cell Res (2015) 339:163–73. doi:10.1016/j.yexcr.2015.10.032
48. Yanagawa Y, Matsumoto M, Togashi H. Adrenoceptor-mediated enhancement of interleukin-33 production by dendritic cells. Brain Behav Immun (2011) 25:1427–33. doi:10.1016/j.bbi.2011.04.012
49. Goyarts E, Matsui M, Mamnone T, Bender AM, Wagner JA, Maes D, et al. Norepinephrine modulates human dendritic cell activation by altering cytokine release. Exp Dermatol (2008) 17:188–96. doi:10.1111/j.1600-0625.2007.00677.x
50. Maestroni GJ, Mazzola P. Langerhans cells beta 2-adrenergic receptors: role in migration, cytokine production, Th priming and contact hypersensitivity. J Neuroimmunol (2003) 144:91–9. doi:10.1016/j.jneuroim.2003.08.039
51. Yang H, Du RZ, Qiu JP, Tang YQ, Chen SC. Bisoprolol reverses beta-Adrenergic receptor mediated increases in activation and function of human natural killer (CD16+). Cancer Res (2010) 70:7042–52. doi:10.1158/0008-5472.bcbi.2016.07.162
52. Shacknagh H, Linaid T, Shingk K. Suppression of phagosome proteolysis and Matrigel migration with the alpha2-adrenergic receptor agonist dexamethasone in murine dendritic cells. Immunopharmacology Immunotoxicology (2013) 35:558–66. doi:10.3109/08923973.2013.822509
53. Ueshima H, Inada T, Shingu K. Suppression of phagosome proteolysis and Matrigel migration with the alpha2-adrenergic receptor agonist dexamethasone in murine dendritic cells. Immunopharmacology Immunotoxicology (2013) 35:558–66. doi:10.3109/08923973.2013.822509
54. De Lorenzo BH, de Oliveira Marchioro L, Greco CR, Suchecki D. Sleep deprivation reduces NK cell number and function mediated by beta-adrenergic signalling. Psychoneuroendocrinology (2015) 57:134–43. doi:10.1016/j.psyneuen.2015.04.006
55. De Lorenzo BH, de Oliveira Marchioro L, Greco CR, Suchecki D. Sleep deprivation reduces NK cell number and function mediated by beta-adrenergic signalling. Psychoneuroendocrinology (2015) 57:134–43. doi:10.1016/j.psyneuen.2015.04.006
80. Simonini MV, Polak PE, Sharp A, McGuire S, Galea E, Feinstein DL.

68. Song Y, Gan Y, Wang Q, Meng Z, Li G, Shen Y, et al. Enriching the housing environment for mice enhances their NK cell antitumor immunity via sympathetic nerve-dependent regulation of NKGD2 and CCR5. *Cancer Res* (2017) 77:1611–22. doi:10.1158/0008-5472.CAN-16-2143

87. Szpunar MJ, Belcher EK, Dawes RP, Madden KS. Sympathetic innervation, norepinephrine content, and norepinephrine turnover in orthotopic and spontaneous models of breast cancer. *Brain Behav Immun* (2016) 53:223–33. doi:10.1016/j.bbi.2015.04.011

88. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nat Med* (2006) 12:939–44. doi:10.1038/nm1447

89. Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, et al. A stress response pathway regulates DNA damage through beta-adrenergoreceptors and beta-arrestin-1. *Nature* (2011) 477:349–53. doi:10.1038/nature10368

90. Hara MR, Sachs BD, Caron MG, Lefkowitz RJ. Pharmacological blockade of a beta(2)AR-beta-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model. *Cell Cycle* (2013) 12:2119–24. doi:10.1002/cell.23368

91. Flint MS, Baum A, Episcopo B, Knickelbein KZ, Lieyeg Dougall AJ, Chambers WH, et al. Chronic exposure to stress hormones promotes transformation and tumorigenicity of 3T3 mouse fibroblasts. *Stress* (2013) 16:114–21. doi:10.3109/10253839.2012.686075

92. Cole SW, Nagaraja AS, Lutgendtov SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. *Nat Rev Cancer* (2015) 15:563–72. doi:10.1038/nrc3978

93. Mathur MB, Epe D, Kind S, Desai M, Parks CG, Sandler DP, et al. Perceived stress and telomere length: a systematic review, meta-analysis, and methodologic considerations for advancing the field. *Brain Behav Immun* (2016) 54:158–69. doi:10.1016/j.bbi.2016.02.002

94. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* (2011) 20:1238–50. doi:10.1158/1055-9965.EPI-11-0005

95. Huang XY, Wang HC, Yuan Z, Huang J, Zheng Q. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via beta-adrenergic receptor-dependent activation of P38/MAPK pathway. *Hepatogastroenterology* (2012) 59:889–93. doi:10.18632/hje.2012.387

96. Wu PQ, Fang T, Yu LX, LV GS, LW HW, Liang D, et al. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1alpha. *Hepatol* (2016) 65:314–24. doi:10.1002/jhep.2016.04.019

97. Coelho M, Soares-Silva C, Brando D, Marino F, Cosentino M, Ribeiro L. beta-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. *J Cancer Res Clin Oncol* (2017) 143:275–91. doi:10.1007/s00432-016-2278-1

98. Dal Monte M, Fornaciari I, Nicchia GP, Casini G, Bagnoli P. beta3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling. *Naunyn Schmiedebergs Arch Pharmacol* (2014) 387:573–83. doi:10.1007/s00210-014-0969-1

99. Lin X, Luo K, LV Z, Huang J. Beta-adrenergoreceptor action on pancreatic cancer cell proliferation and tumor growth in mice. *Hepatogastroenterology* (2012) 59:584–8. doi:10.5754/hje.11271

100. Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang F, et al. beta2-adrenergoreceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. *Eur J Pharmacol* (2011) 655:3–7. doi:10.1016/j.ejphar.2011.04.055

101. Zhang D, Ma Q, Shen S, Hu H. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenergoreceptor antagonists anticancer effect in pancreatic cancer cell. *Pancreas* (2009) 38:94–100. doi:10.1097/MPA.0b013e318184f50c

102. Zhou C, Chen X, Zeng W, Peng C, Huang G, Li X, et al. Propranolol induces apoptosis in pancreatic cancer cell via AKT/ MAPK pathway. *Oncotarget* (2016) 7:68314–27. doi:10.18632/oncotarget.11599

103. Zhang D, Ma Q, Wang Z, Zhang M, Guo K, Wang F, et al. beta2-adrenergoreceptor blockage induces G1/S phase arrest and apoptosis in melanoma cells via AKT/ MAPK pathway. *Oncotarget* (2016) 7:11599–60. doi:10.18632/oncotarget.11599
efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget (2011) 2:797–809. doi:10.18632/oncotarget.343

106. Shroy AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 120:1515–23. doi:10.1172/JCI40802

107. Zhang J, Deng YT, Liu J, Wang YQ, Yi TW, Huang BY, et al. Norepinephrine induced epithelial-mesenchymal transition in HT-29 and A549 cells in vitro. J Cancer Res Clin Oncol (2016) 142:423–35. doi:10.1007/s00432-015-2044-9

108. Pu J, Zhang X, Luo H, Xu L, Lu X, Lu J. Adrenaline promotes epithelial-to-mesenchymal transition via Huk-TGFBeta regulatory axis in pancreatic cancer cells and the implication in cancer prognosis. Biochim Biophys Res Commun (2017) 493:1273–9. doi:10.1016/j.bbrc.2017.09.146

109. Lu YJ, Geng ZI, Sun XY, Li YH, Fu XR, Zhao XY, et al. Isoprenaline induces epithelial-mesenchymal transition in gastric cancer cells. Mol Cell Biochem (2015) 408:1–13. doi:10.1007/s11010-015-2477-0

110. Shan T, Cui X, Li W, Lin W, Li Y, Chen X, et al. Novel regulatory program for norepinephrine-induced epithelial-mesenchymal transition in gastric adenocarcinoma cell lines. Cancer Sci (2014) 105:847–56. doi:10.1111/cas.12438

111. Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, et al. Biobehavioral modulation of the eosinophic transcriptome in cancer patients with chronic stress. J Clin Invest (2012) 124:13175–86. doi:10.1172/JCI61317

112. Le CP, Sloan EK. Stress-driven lymphatic dissemination: an unanticipated consequence of communication between the sympathetic nervous system and lymphatic vasculature. Mol Cell Oncol (2016) 3:e1177674. doi:10.1080/23723556.2016.1177674

113. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, et al. Src activation by beta-adrenoceptor is a key switch for tumour metastasis. Nat Commun (2013) 4:1403. doi:10.1038/ncomms2903

114. Benish M, Barta I, Goldfarb Y, Levi B, Avraham A, Raz A, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol (2008) 15:2042–52. doi:10.1245/s10434-008-9890-5

115. Campbell JP, Karolak MR, Ma Y, Perren DS, Masood-Campbell SK, Penner NL, et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. Proc Natl Acad Sci U S A (2010) 107:965–70. doi:10.1073/pnas.0910332107

116. Elefteriou F. Chronic stress, sympathetic activation and skeletal metastasis of cancer cells in BALB/c nude mice is inhibited by beta-blockers. Oncogene (2008) 27:6435–43. doi:10.1038/onc.2008.166

117. Zhang J, Deng YT, Luo H, Xu L, Lu X, Lu J. Adrenaline promotes epithelial-to-mesenchymal transition in gastric cancer cells. Mol Cell Biochem (2015) 408:1–13. doi:10.1007/s11010-015-2477-0

118. Chen H, Liu D, Guo L, Cheng X, Guo N, Shi M. Chronic psychological stress promotes lung metastatic colonization of circulating breast cancer cells by decorating a pre-metastatic niche through activating beta-adrenergic signaling. J Pathol (2018) 244:49–60. doi:10.1002/path.4988

119. Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, et al. β-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy. Cancer Res (2017) 77(20):5639–51. doi:10.1158/0008-5472.CAN-17-0546

120. Wrobel JL, Bod L, Lengagne R, Kato M, Prevost-Blondel A, Le Gal FA. Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma. Oncotarget (2016) 7:77925–37. doi:10.18632/oncotarget.12833

121. Kokolus KM, Capitano ML, Lee CT, Eng JW, Waight JD, Hylander BL, et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc Natl Acad Sci U S A (2013) 110:20176–81. doi:10.1073/pnas.1304291110

122. Schmidt D, Peterlik D, Reber SO, Lechner A, Mannel DN. Induction of suppressor cells and increased tumor growth following chronic psychosocial stress in male mice. Proc Natl Acad Sci U S A (2016) 113:20176–81. doi:10.1073/pnas.1304291110

123. Zhou L, Li Y, Li X, Chen G, Liang H, Wu Y, et al. Propranolol attenuates surgical stress-induced elevation of the regulatory T cell response in patients undergoing radical mastectomy. J Immunol (2016) 196:3460–9. doi:10.4049/jimmunol.1501677

124. Jia J, Wang X, Wang Q, Guo X, Cao J, Zhang X, et al. Chronic psychological stress induces the accumulation of myeloid-derived suppressor cells in mice. Proc Natl Acad Sci U S A (2013) 110:20176–81. doi:10.1073/pnas.1304291110

125. Szabo S, Tache Y, Somogyi A. The legacy of Hans Selye and the origins of stress research: a retrospective 75 years after his landmark brief “letter” to the editor of nature. Stress (2012) 15(5):722–78.

126. Goldberg DS. Catecholamines and stress. Endor Regul (2003) 37:69–80.

127. Stankiewicz AM, Gosick I, Majewska A, Swiergiel AH, Juszczak GR. The effect of acute and chronic social stress on the hippocampal...
transcriptome in mice. PLoS One (2015) 10:e0142195, doi:10.1371/journal.pone.0142195

143. Lin Q, Wang F, Yang R, Zheng X, Gao H, Zhang P. Effect of chronic restraint stress on human colorectal carcinoma growth in mice. PLoS One (2013) 8:e61435, doi:10.1371/journal.pone.0061435

144. Madden KS, Szpunar MJ, Brown EB. Early impact of social isolation and breast tumor progression in mice. Brain Behav Immun (2013) 30(Suppl):S135–41. doi:10.1016/j.bbi.2012.05.003

145. Hou N, Zhang X, Zhao L, Xiao X, Li Z, Song T, et al. A novel chronic stress-induced shift in the Th1 to Th2 response promotes colon cancer growth. Biochem Biophys Res Commun (2013) 439:471–6. doi:10.1016/j.bbrc.2013.08.101

146. Partheck LI, Steeparforck S, Kading A, Seubert F, Kuhn S, Lorenz E, et al. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Pancreatology (2016) 16:423–33. doi:10.1016/j.pan.2016.03.005

147. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 15:2695–702. doi:10.1158/1078-0432.CCR-08-2966

148. Dethlefsen C, Hansen LS, Lillelund C, Andersen C, Gehl J, Christensen JF. National Research Council (US) Committee for the Update of the Guide

149. Demas GE, Carlton ED. Ecoimmunology for psychoneuroimmunologists: a rapid overview. J Transl Med (2014) 12:278. doi:10.1186/1479-5876-12-278

150. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press, (2011).

151. Hylander BL, Repasya EA. Thermoneutrality, mice and cancer: a heated opinion. Trends Cancer (2016) 2:166–75. doi:10.1016/j.trencan.2016.03.005

152. Karp CL. Unstressing intemperate models: how cold stress undermines the anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 118:1991–2001. doi:10.1172/JCI35180

153. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 39:74–88. doi:10.1016/j.immuni.2013.06.014

154. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 2:95. doi:10.3389/fonc.2012.00095

155. Giles DA, Moreno-Fernandez ME, Stankiewicz TE, Grapeunetter S, Cappelletti M, Wu D, et al. Thermoneural stress exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease but not insulin resistance. Mol Metab (2016) 5:1121–30. doi:10.1016/j.molmet.2016.09.008

156. Gaskill BN, Garner JP. Stressed out: providing laboratory animals with behavioral control to reduce the physiological effects of stress. Lab Anim (NY) (2003) 37:1489–94. doi:10.1177/002367720303700801

157. Demas GE, Carlton ED. Ecoimmunology for psychoneuroimmunologists: considering context in neuroendocrine-immune-behavior interactions. Brain Behav Immun (2015) 49:9–16. doi:10.1016/j.bbi.2014.09.002

158. Kondratsenko TY, Zacharovs JV, Kuzina NV, Katokov V, Severin ES, Korolova Z, et al. Activation and immunoprofiling in cancer: an update from the melanoma and immuno-notherapy bridge 2015. J Transl Med (2016) 14:273. doi:10.1186/s12967-016-1029-z

159. Gaskill BN, Garner JP. Stressed out: providing laboratory animals with behavioral control to reduce the physiological effects of stress. Lab Anim (NY) (2012) 46:142–5. doi:10.1177/0023677212128104

160. Hicks BM, Murray LJ, Powe DG, Hughes CM, Cardwell CR. beta-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Int J Epidemiol (2013) 42:851–62. doi:10.1093/ije/dyt196

161. Cardwell CR, Coleman HG.anj Malignant brain tumors. Oncol Lett (2013) 5:221–5. doi:10.3892/ol.2012.989

162. Whitsett JA, Burdsall J, Workman L, Hollinger B, Neely J. beta-Adrenergic adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest (2013) 93:279–90. doi:10.1038/labinvest.2012.175

163. Saints JB, Pasco DS, Salas RD, Feller DR. Evaluation of beta-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP. Biochem Mol Biol Int (1993) 29:123–30.

164. Sardi I, Giunti L, Bresci C, Buccoliero AM, Degl’innocenti D, Cardellicchio S, et al. Expression of beta-adrenergic receptors in pediatric malignant brain tumors.Oncol Lett (2013) 5:221–5. doi:10.3892/ol.2012.989

165. Williams JW, Elvington A, Ivanov S, Kessler S, Luehmann H, Baba O, et al. Impact of nesting material on mouse body temperature and physiology. Physiol Behav (2013) 110:87–95. doi:10.1016/j.physbeh.2012.12.018

166. Sardi I, Giunti L, Bresci C, Buccoliero AM, Degl’innocenti D, Cardellicchio S, et al. Expression of beta-adrenergic receptors in pediatric malignant brain tumors. Oncol Lett (2013) 5:221–5. doi:10.3892/ol.2012.989

167. Whitsett JA, Burdsall J, Workman L, Hollinger B, Neely J. beta-Adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP. Biochem Mol Biol Int (1993) 29:123–30.

168. Sardi I, Giunti L, Bresci C, Buccoliero AM, Degl’innocenti D, Cardellicchio S, et al. Expression of beta-adrenergic receptors in pediatric malignant brain tumors. Oncol Lett (2013) 5:221–5. doi:10.3892/ol.2012.989

169. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 2:95. doi:10.3389/fonc.2012.00095

170. Gaskill BN, Garner JP. Stressed out: providing laboratory animals with behavioral control to reduce the physiological effects of stress. Lab Anim (NY) (2012) 46:142–5. doi:10.1177/0023677212128104

171. Gaskill BN, Garner JP. Stressed out: providing laboratory animals with behavioral control to reduce the physiological effects of stress. Lab Anim (NY) (2012) 46:142–5. doi:10.1177/0023677212128104

172. Gaskill BN, Garner JP. Stressed out: providing laboratory animals with behavioral control to reduce the physiological effects of stress. Lab Anim (NY) (2012) 46:142–5. doi:10.1177/0023677212128104

173. Gaskill BN, Garner JP. Stressed out: providing laboratory animals with behavioral control to reduce the physiological effects of stress. Lab Anim (NY) (2012) 46:142–5. doi:10.1177/0023677212128104

174. Gaskill BN, Garner JP. Stressed out: providing laboratory animals with behavioral control to reduce the physiological effects of stress. Lab Anim (NY) (2012) 46:142–5. doi:10.1177/0023677212128104

175. Sardi I, Giunti L, Bresci C, Buccoliero AM, Degl’innocenti D, Cardellicchio S, et al. Expression of beta-adrenergic receptors in pediatric malignant brain tumors. Oncol Lett (2013) 5:221–5. doi:10.3892/ol.2012.989

176. Sardi I, Giunti L, Bresci C, Buccoliero AM, Degl’innocenti D, Cardellicchio S, et al. Expression of beta-adrenergic receptors in pediatric malignant brain tumors. Oncol Lett (2013) 5:221–5. doi:10.3892/ol.2012.989
McCourt C, Coleman HG, Murray LJ, Cantwell MM, Dolan O, Powe DG, et al. Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. Br J Dermatol (2014) 170: 930–8. doi:10.1111/bjd.12894

Parker WP, Lohse CM, Zaid HB, Cheville JC, Boorjian SA, Leibovich BC, et al. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. Urol Oncol (2017) 35:36.e31–6. doi:10.1016/j.urolonc.2016.08.013

Yang P, Deng W, Han Y, Shi Y, Xu T, Shi J, et al. Analysis of the correlation among hypertension, the intake of beta-blockers, and overall survival outcome in patients undergoing chemotherapy with inoperable stage III non-small cell lung cancer. Am J Cancer Res (2017) 7:946–54.

Kokohus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology (2017) 7(3). doi:10.21687/euro2017.1405205

Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate (2013) 73:250–60. doi:10.1002/pros.22564

Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol (2014) 65:635–41. doi:10.1016/j.eururo.2013.01.007

Kaapu KJ, Ahl J, Tammela TL, Auvinen A, Murtola TJ, Sotalol, but not digoxin is associated with decreased prostate cancer risk: a population-based case-control study. Int J Cancer (2015) 137:1187–95. doi:10.1002/ijc.29470

De Giorgi V, Grazzini M, Gandini S, Benemei S, Marchionni N, Botteri E, Pennacchioli E, et al. Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol (2017). doi:10.1001/jamaoncol.2017.2908

Pantziaraki P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP. Repurposing drugs in oncology (ReDO)-propranolol as an anti-cancer agent. Ercancermedicalscience (2016) 10:680. doi:10.3332/ercancer.2016.680

Albinava V, Escriva RMJ, Soler I, Padial LR, Recio-Poveda L, Villar Gomez de Las Heras K, et al. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet J Rare Dis (2017) 12:122. doi:10.1186/s12023-017-0664-7

Leaute-Labreze C, Boccarda O, Degurgullier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbe G, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics (2016) 138. doi:10.1542/peds.2016-0353

Yun YJ, Gyon YH, Yang S, Lee YK, Park J, Park M. A prospective study to assess the efficacy and safety of oral propranolol as first-line treatment for infantile superficial hemangioma. Korean J Pediatr (2015) 58:484–90. doi:10.3345/kjp.2015.58.12.484

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Qiao, Chen, Buscek, Repasky and Hylander. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.